MorphoSys AG : Novartis' offer of € 68 per share looks attractive for MorphoSys shareholders
>Novartis to pay € 68 per MorphoSys share - Yesterday (5 February) after US market close, MorphoSys and Novartis announced that Novartis is launching a voluntary public takeover offer for all MorphoSys shares at a price of € 68 per share. The offer is subject to customary closing conditions, in particular a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory approvals. The closing is currently expected to take place in the first half of 202...MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.